A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

NCT04993430 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

ER-Positive, HER2-Negative Breast Cancer

Interventions

DRUG: HRS8807
DRUG: HRS8807
DEVICE: HRS8807、SHR6390
DRUG: HRS8807、SHR6390

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.